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Kidney Transplantation

Financial Evaluation of Kidney Transplant
With Hepatitis C Viremic Donors to Uninfected
Recipients
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David A. Axelrod, MD, MBA,1 Krista L. Lentine, MD, PhD,2 Ramji Balakrishnan, PhD,1
Su-Hsin Chang, PhD,3 Terek Alhamad, MD,3 Huiling Xiao, MS,2 Bertran L. Kasiske, MD,4
Roy D. Bloom, MD,5 and Mark A. Schnitzler, PhD2

Background. Kidney transplantation with hepatitis C viremic (dHCV+) donors appears safe for recipients without HCV
when accompanied by direct acting antiviral (DAA) treatment. However, US programs have been reluctant to embrace this
approach due to concern about insurance coverage. While the cost of DAA treatment is currently offset by the reduction
in waiting time, increased competition for dHCV+ organs may reduce this advantage. This analysis sought to demonstrate
the financial benefit of dHCV+ transplant for third-party health insurers to expand coverage availability. Methods. An
economic analysis was developed using a Markov model for 2 decisions: first, to accept a dHCV+ organ versus wait for a
dHCV uninfected organ; or second, accept a high kidney donor profile index (KDPI) (>85) organ versus wait for a better quality dHCV+ organ. The analysis used Medicare payments, historical survival data, cost report data, and an estimated cost of
DAA of $29 874. Results. In the first analysis, using dHCV+ kidneys reduced the cost of end-stage kidney disease care
if the wait for a dHCV uninfected organ exceeded 11.5 months. The financial breakeven point differed according to the cost
of DAA treatment. In the second analysis, declining a high-KDPI organ in favor of a waiting dHCV+ organ was marginally
clinically beneficial if waiting times were <12 months but not cost effective. Conclusions. dHCV+ transplant appears to
be economically and clinically advantageous compared with waiting for dHCV-uninfected transplant but should not replace
high-KDPI transplant when appropriate. Despite the high cost of DAA therapy, health insurers benefit financially from dHCV+
transplant within 1 year.
(Transplantation Direct 2020;6: e627; doi: 10.1097/TXD.0000000000001056. Published online 10 November, 2020.)

INTRODUCTION
The need for kidney transplant continues to greatly exceed
the available organ supply, as over 90 000 US residents
are currently waiting for an organ.1 Consequently, every
year thousands of patients die or are removed from the
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transplant waiting list before being offered an organ. At
the same time, the rate of discard of potentially transplantable kidney allografts remains substantial.2 Active donor
infection with hepatitis C virus (dHCV+), defined as evidence of active viral replication by nucleic acid testing,
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has historically increased the risk of kidney nonutilization.3 While use of dHCV+ organs in patients with active
HCV has increased, the population of potentially acceptable HCV-infected recipients remains small, limiting use
of these organs if only infected patients are transplanted.
The landscape of HCV treatment changed in 2014 with
the introduction of the first effective direct acting antiviral
agents (DAAs), although the need for ribavirin limited their
use in patients with renal dysfunction.4 DAA treatment of
HCV has been shown to be highly effective in achieving a
sustained viral response (SVR), defined as no detectable virus
at 12 weeks. Recently, new regimens have been developed
that overcome early limitations, allowing treatment all HCV
genotypes in patients with kidney failure and after transplant.
In this context, 2 landmark trials demonstrated that dHCV+
kidneys can be safely used in HCV-uninfected patients who
are treated with DAAs shortly after transplant.5,6 Patients
transplanted under these protocols waited <2 months for
transplant, compared with 4–7 years for patients waiting for
non-HCV infected organs. While clinically beneficial, broader
use of these protocols had been limited by cost, as early
commercially available DAA regimens exceeded $80 000.7
Fortunately, competition has reduced the price of treatment
substantially. Despite this reduction in cost, transplant programs remain reluctant to expand use of these organs due to
concern about insurance coverage.7
To facilitate broad adoption of dHCV+ organ utilization,
transplant centers need assurance that third-party health
insurers will provide coverage for necessary DAAs. However,
from a financial perspective, private insurance carriers do
not bear the costs of life-long renal replacement therapy
nor benefit from expansion of organ supply associated with
the use of these organs. Therefore, the incremental cost of
DAAs to clear HCV infection acquired from dHCV+ organs
needs to be offset by a sufficient reduction dialysis time.
The economic breakeven point needed is a function of the
cost of DAA therapy, which is rapidly declining as shorter
courses of treatment are demonstrated to be effective. To
better understand the financial implications of using dHCV+
kidney transplant in HCV-uninfected recipients, we sought
to estimate the minimal waiting time reduction required to
justify acceptance of dHCV+ organs over a range of DAA
treatment prices.

MATERIALS AND METHODS
Data Sources and Approval
This study used data from the US Renal Data System,
the Scientific Registry of Transplant Recipients (SRTR), and
transplant hospital Medicare Costs Reports (Table 1). The
US Renal Data System database includes payment data for
all patients on maintenance renal replacement therapy with
Medicare as their primary insurance, including professional
charges and payments for hospitalizations. The SRTR system includes data on all donors, waitlisted candidates, and
transplant recipients in the United States, submitted by the
members of the Organ Procurement and Transplantation
Network. The Health Resources and Services Administration,
US Department of Health and Human Services, provides
oversight of the activities of the Organ Procurement and
Transplantation Network and SRTR contractors. National
Medicare Cost Report data were obtained under a Freedom

TABLE 1.

Data elements included in cost-effectiveness models
Model
Dialysis

KDPI=20-85
KDPI=20-85
KDPI=20-85
KDPI=20-85
KDPI=20-85
KDPI=20-85
KDPI=20-85
KDPI> 85
KDPI> 85
KDPI> 85
KDPI> 85
KDPI> 85
KDPI> 85
KDPI> 85
dHCV+
dHCV+
dHCV+
dHCV+
dHCV+
dHCV+
dHCV+
dHCV+
dHCV+

Data element
Cost per mo of dialysis
Waitlist mortality (age 48)
Waitlist mortality (age 65)
Cost of transplant
Cost report payment
Total cost of transplant
Annual cost after transplant (first yr)
Annual cost after transplant 13–24 mo
Graft failure rate (pts/mo)
Death rate (pts/mo)
Cost of transplant
Cost report payment
Total cost of transplant
Annual cost after transplant (first yr)
Annual cost after transplant 13–24 mo
Graft failure rate (pts/mo)
Death rate (pts/mo)
Cost of transplant
Cost report payment
Cost of DAA (Mavyret)

Basecase
value
$4753
0.41%
0.67%
$29 765
$68 567
$98 332
$34 292
$14 049
0.170%
0.190%
$31 557
$68 567
$100 124
$43 316
$19 340
0.3%
0.3%
$33 332
$68 567
$27 610

Source
Medicare (part A/B)
SRTR
SRTR
Medicare (part A/B)
Medicare cost report
Medicare (part A/B)
Medicare (part A/B)
SRTR annual report
SRTR annual report
Medicare (part A/B)
Medicare cost report

Medicare (part A/B)
Medicare (part A/B)
SRTR annual report
SRTR annual report
Medicare (part A/B)
Medicare cost report
Average wholesale
price
Cost of labs (PCR X6, LFTs X4)
$2265 Medicare (part A/B)
Total cost of transplant
$131 733
Annual cost after transplant (first yr) $34 292 Medicare (part A/B)
Annual cost after transplant 13–24 mo $14 049 Medicare (part A/B)
Graft failure rate (pts/mo)
0.150% SRTR annual report
Death rate (pts/mo)
0.150% SRTR annual report

DAA, direct acting antiviral; KDPI, kidney donor profile index; LFTs, liver function tests; SRTR,
Scientific Registry of Transplant Recipients.

of Information Act request. This study was approved by the
Saint Louis University Institutional Review Board.
This analysis was conducted from the health insurer
(Medicare) perspective using methods described in previous
publications.8 Medicare claims for 18 037 kidney transplant
procedures performed from 2014 to 2016 were reviewed.
Payments for technical services (part A) and professional services/immunosuppression (part B) were aggregated for 3 categories of costs that relate to distinct periods:
• First, the cost of maintaining a patient on the kidney
transplant waiting list (pretransplant) including the cost
of hemodialysis for patients not listed preemptively.
Medicare payments were aggregated for patients who
were listed on the national US waiting list to determine
an average monthly cost.
• Second, the cost of the transplant episode including the
transplant and initial postoperative care was determined
as the mean payment (parts A and B). In addition, mean
national payment per kidney via the Medicare cost report
was included based on data from 154 transplant centers
obtained via a freedom of information act request (full
data not shown). For patients who receive DAA treatment
for HCV infection, the cost of medication, physician visits,
and laboratory tests were included during this period.
• Third, posttransplant cost for technical services (part
A) and professional services/ immunosuppression (part

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.

B) were aggregated. Posttransplant cost did not include
medication coverage under part D.
• The cost of graft failure and patient death were derived
from Medicare payments for the month of the graft loss.
The basecase cost of DAA therapy was calculated from
clinical trial protocols and Medicare allowable payments. The
basecase included a 12-week course of glecaprevir/pibrentasvir, which has an average wholesale price of $9203 per 4-week
course (Micromedex Redbook, Accessed February 17, 2020),
3 visits to a hepatologist including liver function tests ($240
per visit), and HCV PCR tests at week 0, 2, 4, 8, 12, and 24
($257 per test). Total cost of basecase DAA treatment was
$29 875. Sensitivity analyses examined costs from $5000 to
$65 000 per treatment course.
Mortality rates for patients on the transplant waiting list
and patient and graft survival after transplant were derived
from transplant registry (SRTR) data based on kidney donor
profile index (KDPI) for high- (>85) and lower-KDPI (≤85)
organs, as reported in the SRTR annual report. Because
patients who consent for high KDPI organs systematically differ from patients who do not consent to receive these organs,
waitlist survival was modeled separately. For the lower KDPI
analysis, waitlist survival was modeled for a 48-year-old
patient; for the high KDPI analysis, waitlist mortality was
modeled for a 65-year-old patient. Similarly, graft failure rates
were derived from transplant registry analyses. Differences in
patient and graft survival were calculated at 36 months after
initial offer for this analysis.1
Analyses
A multistate Markov model was constructed including
waitlist, transplanted, graft failure with return to dialysis,
and death states. Transition probabilities were determined
from published literature as summarized in Table 1. Patients
can transition to death before transplant at rates based on
the waitlisted population, after transplant with a functioning
graft, or after graft failure. A 36-month model was constructed
without discounting given the offsetting medical cost inflation
and time value of money over this short period of analysis. A
36-month analysis was chosen as this coincides with current
Medicare payment policy for transplant and provides a reasonable period for a health insurer to derive financial benefit.
Logically, patients offered a dHCV+ donor and dHCVuninfected donor at the same time with equal or better KDPI
will choose the uninfected organ. Therefore, decision analytic
models were constructed to compare cost and outcomes for
2 scenarios. The first considered a waitlist patient offered the
choice of accepting a dHCV+ organ (with DAA treatment)
or waiting for a dHCV-uninfected organ of similar or better
quality as defined by KDPI. For this analysis, we calculated
the point of cost equivalence between accepting a dHCV+/
lower KDPI (≤85) kidney with waiting for a dHCV-uninfected
organ of similar quality. The second scenario examined the
choice of accepting a dHCV-uninfected/high KDPI kidney or
waiting for a longer lasting lower-KDPI dHCV+ organ. This
decision analysis reflects patients’ desire to wait for a lower
KDPI kidney with the hope longer graft survival and the
promise that a dHCV+ donor organ can be identified with
only a short incremental waiting time.
Aggregated costs for kidney transplant were calculated for
dHCV-uninfected/lower KDPI transplant, dHCV-uninfected/
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high KDPI transplant, and dHCV+ transplant using the
input data summarized in Table 1 to determine the time to
cost equivalence. Patients with a graft failure were assumed
to return to dialysis until the end of the period of analysis.
Secondary analysis included patient survival and the costeffectiveness as determined by the cost per year of life saved
to 36 months. Strategies which both increased life expectancy
and lower spending were labeled as dominant. Sensitivity
analyses examined the economic impact of varying the anticipated reduction in waiting time (between 0 and 30 mo) and
the anticipated costs of DAA treatment.

RESULTS
In the base analysis, cost of dHCV+ kidney transplant
($131 772) significantly exceeded the cost of dHCV-uninfected/
lower KDPI kidney transplant ($98 332) and dHCV-uninfected/
high KDPI transplant ($100 124). This cost reflects the need
for DAA therapy ($29 874 per treatment). The cost of dialysis for 36 months was $171 108. Three-year graft and patient
survival were essentially equivalent for dHCV-uninfected (87%
and 93%) and dHCV+ (89% and 95%) lower KDPI kidney
transplant but were lower for dHCV-uninfected/high KDPI
transplant recipients (77% and 88%). Survival on dialysis at 36
months was 86.3% for lower-KDPI only consented candidates
and 78.5% for high KDPI consented patients.
In the basecase analysis, the total cost of care over 36
months was compared for patients who underwent transplant
with a dHCV+/lower KDPI kidney and those who waited for a
dHCV-uninfected organ. At 11.5 months, the cost of care was
equivalent between the 2 strategies ($201 049 for immediate
dHCV+ kidney transplant, $200 779 for a delayed dHCVuninfected kidney transplant). Accepting dHCV+ transplant
resulted in improved 3-year expected survival (94.7%), compared with waiting for a dHCV-uninfected organ (91.0%).
Accepting a dHCV+ organ which reduced waiting times for
transplant <11.5 months was associated with higher costs but
greater survival compared with waiting for dHCV-uninfected
transplant (Table 2). However, if a dHCV-uninfected organ
was available in <6 months, dHCV+ was no longer cost effective (>$100 000 per life-year saved) over a 36-month analysis
(Table 2). Sensitivity analysis confirmed that as the cost of
DAA decreased, necessary waiting time reduction to achieve
breakeven cost similarly decreased. For example, if the time
to transplant with a dHCV− organ was only 6 months, the
cost of DAA would need to decrease to <$15 000 to remain
cost effective.
In the second analysis, accepting a dHCV-uninfected/high
KDPI organ now was compared with waiting for a dHCV+/
lower KDPI organ. Over the 36 months, accepting a high KDPI
organ was associated with lower total cost unless DAA treatment was <$5000 even if offered simultaneously. Waiting for a
dHCV+/lower KDPI organ for up to 12 months was associated
with a small survival benefit at 36 months, while immediate
acceptance KDPI organ is preferred for longer waiting periods. However, given the high incremental cost of DAA therapy,
declining a dHCV-uninfected/high KDPI organ to wait for a
dHCV/lower KDPI was not cost effective (Table 3).

DISCUSSION
Use of dHCV+ kidney transplant in recipients without
HCV infection has been demonstrated to improve access to
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TABLE 2.

Two-way sensitivity analysis showing the cost per year of life saved by accepting a dHCV+ kidney rather than waiting for
a dHCV-uninfected kidney
Anticipated reduction in waiting time
Cost of DAA
$5000
$10 000
$15 000
$20 000
$25 000
$30 000
$35 000
$40 000
$45 000
$50 000
$55 000
$60 000

3

6

9

12

18

24

30

$100 038
$184 516
$268 994
$353 472
$437 950
$522 428
$606 906
$691 384
$775 862
$860 340
$944 818
$1 029 296

dHCV+ DOM
dHCV+ DOM
$63 365
$127 840
$192 315
$256 791
$321 266
$385 741
$450 216
$514 691
$579 167
$643 642

dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
$41 202
$93 399
$145 596
$197 794
$249 991
$302 189
$354 386
$406 583

dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
$26 506
$70 400
$114 294
$158 188
$202 082
$245 976

dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
$8573
$41 953

dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM

dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM
dHCV+ DOM

The cost of DAA therapy varies from $5000 to $60 000 and the time to first dHCV− kidney from 3 mo to 30 mo. The total period of analysis is 36 mo.
Green, cost effective; blue, survival improved but not cost effective; black, survival not improved despite higher cost.
DAA, direct acting antiviral; dHCV+, hepatitis C viremic donor kidney; DOM, dominant strategy with lower cost and improved survival.

TABLE 3.

Two-way sensitivity analysis showing the cost per year of life saved by accepting a high KDPI kidney rather than waiting
for a dHCV+/lower KDPI kidney
Waiting time for low KDPI/dHCV+ kidney
Cost of DAA
$5000
$10 000
$15 000
$20 000
$25 000
$30 000
$35 000
$40 000
$45 000
$50 000
$55 000
$60 000

3

6

$65 938
$100 617
$135 297
$169 976
$204 655
$239 335
$274 014
$308 694
$343 373
$378 053
$412 732
$447 411

$203 216
$252 873
$302 530
$352 188
$401 845
$451 502
$501 159
$550 816
$600 473
$650 130
$699 788
$749 445

9
$542 235
$628 622
$715 009
$801 396
$887 783
$974 170
$1 060 557
$1 146 944
$1 233 331
$1 319 717
$1 406 104
$1 492 491

12

18

24

30

$2 686 885
$3 004 685
$3 322 485
$3 640 285
$3 958 084
$4 275 884
$4 593 684
$4 911 484
$5 229 283
$5 547 083
$5 864 883
$6 182 683

High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM

High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM

High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM
High KDPI DOM

The cost of DAA therapy varies from $5000 to $60 000 and the time to first dHCV+ kidney from 3 mo to 30 mo. The total period of analysis is 36 mo.
Green, cost effective; blue, survival improved but not cost effective; black, survival not improved despite higher cost.
DAA, direct acting antiviral; DOM, dominant strategy with lower cost and improved survival; KDPI, kidney donor profile index.

kidney transplant, but the financial implications of this strategy are not well defined. Based on this cost analysis of national
US transplant registry and Medicare data, widespread use of
dHCV+ kidney allografts appears justified if acceptance is
associated with shorter waiting times to transplant. Given the
current cost of DAA therapy, a reduction in waiting time of at
least 11.5 months is necessary to demonstrate a cost savings.
Waiting time reductions of at least 6 months were cost-effective at 36 months (based upon a threshold of $100 000 per
life-year), with greater benefit possible as the period of analysis is extended. This calculus is likely to change as demand
for dHCV+ organs increases and the cost of DAA treatment
decreases. In contrast, declining a high KDPI/dHCV− organ
in hope of being offered a lower KDPI/dHCV+ kidney did
not appear to be cost effective. As dHCV+ transplant is more
costly and waitlist mortality is high, it is neither clinically
advantageous nor financially sound over a short-time horizon

to delay transplant if the high-KDPI kidney is otherwise
appropriate.
In the Transplanting Hepatitis C Kidneys into Negative
Kidney Recipients (THINKER) trial, Reese et al9 reported
1-year outcomes of 10 uninfected patients who received
dHCV+ kidneys followed by elbasvir–grazoprevir DAA therapy at the onset of viremia, and 10 additional patients. All
patients achieved SVR with excellent kidney function (mean
creatinine 1.2 mg/dL) at 6 months without evidence of acute
rejection. Patient-reported quality of life was excellent, with
an improvement in the mean physical component summary
on the RAND-36 scale 6.7 (P = 0.012) points from baseline.
In the Exploring Renal Transplants Using Hepatitis C Infected
Donors for HCV-negative Recipients (EXPANDER-1) trial,
Durand et al6 described 10 uninfected patients who underwent dHCV+ transplant with preemptive DAA treatment. All
participants attained SVR at 12 weeks without evidence of

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.

acute rejection and had excellent renal function at the time of
the trial report.
The favorable results of these trials have led to broader
adoption of similar protocols outside of the clinical trial
setting. In 2020, members of the Cleveland Clinic-Florida
transplant program reported their results of dHCV+ transplant across multiple organs (liver, heart, kidney).10,11 In
their protocol, DAA treatment was delayed until patients
were viremic and insurance approval was obtained (median
72 d). The report described transplants in 64 patients
with a mean waiting time of 23.5 days from consent to
transplant. While DAA therapy was not complete for all
patients at the time of reporting, 48 patients achieved SVR
and only 1 was found to have resistant HCV infection
requiring an alternative treatment regimen. Three patients
who underwent kidney transplant from dHCV+ donors
with very low viral loads did not become viremic and thus
were not treated. Importantly, 2 patients developed fibrosing sclerosing hepatitis after delay in DAA initiation (8 and
14 wks), both of whom recovered with DAA therapy and
achieved SVR.
The clinical success of a strategy of dHCV+ kidney transplant combined with DAA treatment has led to significant
reductions in organ discard nationally. The proportion of
patients on the kidney waiting list willing to accept a dHCV+
organ increased from 3% in 2007 to 14% in 2018.3 As
expected, acceptance varies by waiting time. Among newly
listed patients, 22% were willing to accept a dHCV+ organ
while only 13% of patients with 5 years or more waiting
time were willing to accepted a viremic organ. This growing
acceptance of dHCV+ kidney transplants has contributed to
500% increase in the annual number of these transplant performed between 2007 and 2018. One result of these broader
acceptance practices is increased competition for organs,
longer waiting times for a DHCV+ organ, and a reduction
in the cost savings associated with accepting viremic organs.
Before the introduction of DAA, 52.3% of all HCV+ kidneys
were recovered but not transplanted, compared with 16.7%
of non-HCV+ kidneys. Following the introduction of DAAs,
discard of HCV+ kidneys decreased to 37.6% from 2104 to
2017.12 The economic benefits of this practice are contingent
on reducing the time to transplant as compared with waiting
for an uninfected organ. Consequently, alternative allocation
systems may need to be devised to appropriately transplant
these organs into patients most likely to benefit.
Although waiting time benefit is likely to be reduced over
time, overall cost of DAA is also likely to diminish. Recent
studies suggest that “ultra-short” preemptive treatment (immediately before transplant) followed by a 4-day course of treatment can achieve SVR in up to 93% of patients.13 The current
study examines the intersection of these trends to establish a
financial justification for broader adoption of these protocols
in the United States and international contexts. While single
payer systems have the benefit of lifetime recovery of the cost
of HCV therapy improving the cost effectiveness of this treatment, from a purely financial standpoint, currently a patient
who is able to get an uninfected kidney in <12 months and,
instead, is transplanted with an HCV+ kidney uses additional
resources. Conversely, any system that reduces waiting by at
least 11.5 months provides a dominant strategy, as it is both
cost saving and life extending. Therefore, impact on expected
waiting time should be considered in determining the optimal
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patient to receive these valuable organs regardless of payment
system.
Previous analyses of the cost-effectiveness of transplantation of dHCV+ organs differ from the current study in several ways. Kadetz et al assess the cost effectiveness of this
approach in Canada. This analysis considered the lifetime
cost-effectiveness of DHCV+ transplant compared with staying on the waiting list for a year14 and reported an incremental cost effectiveness ratio of $56 018 per QALY. Unlike the
current study, the Canadian study did not assess the minimal
waiting time necessary for cost equivalence/savings for the
health insurer given the national healthcare system in Canada
which benefits from long-term cost savings. In addition, they
assume that 100% of waitlisted patients are on dialysis, while
this analysis included the benefits for all waitlisted patients,
including those not on dialysis. Other analyses have likewise
considered lifetime cost effectiveness analyses rather than
financial analyses of direct cost of care which is most relevant to health insurers who need to determine if they will
support the incremental cost of DAAs.15 Finally, no study
has reported 2 way sensitivity analyses which examines the
impact of simultaneous changes in the cost of DAAs and the
wait time reduction resulting achieved by accepting these
organs. Eckman et al suggest a reduction in time to transplant
of >3 years, which will likely not be true given wider use of
organs, while reductions of <0.7 years were not cost effective. Furthermore, this cost savings assumes patients are on
dialysis. The authors also did not consider the implications of
lower cost of DAA therapy.15
This study is limited by a 3-year window to calculate
cost and benefits. This window was chosen based on the
availability of accurate Medicare payment data, as kidney
transplant-specific Medicare benefits expire at 36 months in
the absence of age older than 65 years or disability. Thus,
to provide an accurate tradeoff between waitlist cost (both
on and off dialysis) and posttransplant expenditures, we
limited the analytic window. We sought to demonstrate the
economic benefit of this treatment strategy over this brief
period to assess the short-term implications of dHCV+ on
total cost of care, which is relevant for payment decisions
for private health insurers and budgeting for national health
systems. Second, we assume SVR with a pan-genotypic medication (glecaprevir/pibrentasvir). Possibly, a small number
of patients may require additional therapy, although in realworld experience retreatment is rare, particularly if treatment is started promptly.16 In addition, some patients who
are transplanted with dHCV+ donors with low viral loads
may not require treatment, further reducing the cost of these
protocols. Finally, we did not perform bootstrapping analyses
to determine significance levels but instead present sensitivity
analyses around the key variables.
In conclusion, use of dHCV+ kidney transplant in uninfected recipients appears to be clinically and financial beneficial in the context of current organ availability and DAA
cost. As the cost of therapy decreases, the waiting time
reduction needed to achieve cost savings will also diminish,
requiring reexamination of this strategy in even in patients
likely to undergo transplant rapidly with a dHCV− organ.
Finally, in patients who consent to receive a high-KDPI
organ, it is not cost-effective to decline transplant with a
dHCV-uninfected/high KDPI organ to wait for a dHCV+/
lower KDPI organ.
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